Clinical trial · no report yet · Phase 3
FORWARD I
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
- NCT02631876 ↗
- Completed
- ImmunoGen, Inc.
- 6 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| Podcasts | 3 | |
| YouTube | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Ovarian Cancer
- Interventions
- Mirvetuximab soravtansine; Paclitaxel; Pegylated liposomal doxorubicin; Topotecan
- Arms
- Mirvetuximab Soravtansine · Experimental
- Investigator's Choice (IC) Chemotherapy · Experimental
- Enrollment
- 366
- Primary outcomes
- Progression-Free Survival (PFS), as Assessed by BIRC Per RECIST Version 1.1 in All Participants Randomized to the Study
- PFS, as Assessed by BIRC Per RECIST Version 1.1 in Participants With High Folate Receptor Alpha Level (≥ 75% of Tumor Staining)
- Sponsor
- ImmunoGen, Inc. with Gynecologic Oncology Group
- Start
- Mar 2, 2016
- Primary completion
- Jan 2019
- Results posted
- Yes
- Registry record
- NCT02631876 · updated Oct 14, 2020
Publications
linked from the registry- Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Konecny GE, Banerjee S, Murphy CG, Tanyi JL, Hirte H, Konner JA, Lim PC, Prasad-Hayes M, Monk BJ, Pautier P, Wang J, Berkenblit A, Vergote I, Birrer MJ. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021 Jun;32(6):757-765. doi: 10.1016/j.annonc.2021.02.017. Epub 2021 Mar 2. PubMed 33667670